Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

180 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase 1 Randomized, Placebo-Controlled, Dose-Escalating Study to Evaluate OVX836, a Nucleoprotein-Based Influenza Vaccine: Intramuscular Results.
Withanage K, De Coster I, Cools N, Viviani S, Tourneur J, Chevandier M, Lambiel M, Willems P, Le Vert A, Nicolas F, Van Damme P. Withanage K, et al. Among authors: viviani s. J Infect Dis. 2022 Aug 12;226(1):119-127. doi: 10.1093/infdis/jiab532. J Infect Dis. 2022. PMID: 34653245 Free PMC article. Clinical Trial.
Antibody persistence after vaccination of adolescents with monovalent and combined acellular pertussis vaccines containing genetically inactivated pertussis toxin: a phase 2/3 randomised, controlled, non-inferiority trial.
Pitisuttithum P, Chokephaibulkit K, Sirivichayakul C, Sricharoenchai S, Dhitavat J, Pitisuthitham A, Phongsamart W, Boonnak K, Lapphra K, Sabmee Y, Wittawatmongkol O, Chauhan M, Wijagkanalan W, Hommalai G, Fortuna L, Chinwangso P, Poredi IK, van den Biggelaar AHJ, Pham HT, Viviani S. Pitisuttithum P, et al. Among authors: viviani s. Lancet Infect Dis. 2018 Nov;18(11):1260-1268. doi: 10.1016/S1473-3099(18)30375-X. Epub 2018 Sep 25. Lancet Infect Dis. 2018. PMID: 30266329 Clinical Trial.
A genetically inactivated two-component acellular pertussis vaccine, alone or combined with tetanus and reduced-dose diphtheria vaccines, in adolescents: a phase 2/3, randomised controlled non-inferiority trial.
Sricharoenchai S, Sirivichayakul C, Chokephaibulkit K, Pitisuttithum P, Dhitavat J, Pitisuthitham A, Phongsamart W, Boonnak K, Lapphra K, Sabmee Y, Wittawatmongkol O, Chinwangso P, Poredi IK, Petre J, Thai PH, Viviani S. Sricharoenchai S, et al. Among authors: viviani s. Lancet Infect Dis. 2018 Jan;18(1):58-67. doi: 10.1016/S1473-3099(17)30612-6. Epub 2017 Oct 20. Lancet Infect Dis. 2018. PMID: 29066131 Clinical Trial.
Measles Susceptibility in Apulia: The Italian Mirror?
Marchi S, Viviani S, Montomoli E, Trombetta CM. Marchi S, et al. Among authors: viviani s. J Infect Dis. 2020 Sep 14;222(8):1414-1415. doi: 10.1093/infdis/jiaa212. J Infect Dis. 2020. PMID: 32343809 No abstract available.
Boosting Teenagers With Acellular Pertussis Vaccines Containing Recombinant or Chemically Inactivated Pertussis Toxin: A Randomized Clinical Trial.
Blanchard Rohner G, Chatzis O, Chinwangso P, Rohr M, Grillet S, Salomon C, Lemaître B, Boonrak P, Lawpoolsri S, Clutterbuck E, Poredi IK, Wijagkanalan W, Spiegel J, Pham HT, Viviani S, Siegrist CA. Blanchard Rohner G, et al. Among authors: viviani s. Clin Infect Dis. 2019 Mar 19;68(7):1213-1222. doi: 10.1093/cid/ciy594. Clin Infect Dis. 2019. PMID: 30759183 Clinical Trial.
Antibody Persistence at 1 and 4 Years Following a Single Dose of MenAfriVac or Quadrivalent Polysaccharide Vaccine in Healthy Subjects Aged 2-29 Years.
Diallo A, Sow SO, Idoko OT, Hirve S, Findlow H, Preziosi MP, Elie C, Kulkarni PS, Parulekar V, Diarra B, Cheick Haidara F, Diallo F, Tapia M, Akinsola AK, Adegbola RA, Bavdekar A, Juvekar S, Chaumont J, Martellet L, Marchetti E, LaForce MF, Plikaytis BD, Enwere GC, Tang Y, Borrow R, Carlone G, Viviani S. Diallo A, et al. Among authors: viviani s. Clin Infect Dis. 2015 Nov 15;61 Suppl 5(Suppl 5):S521-30. doi: 10.1093/cid/civ518. Clin Infect Dis. 2015. PMID: 26553684 Free PMC article. Clinical Trial.
A phase 2 randomized controlled dose-ranging trial of recombinant pertussis booster vaccines containing genetically inactivated pertussis toxin in women of childbearing age.
Chokephaibulkit K, Puthanakit T, Bhat N, Mansouri S, Tang Y, Lapphra K, Rungmaitree S, Anugulruengkitt S, Jantarabenjakul W, Andi-Lolo I, Holt R, Fortuna L, Kerdsomboon C, Chinwangso P, Suwitruengrit L, van den Biggelaar AHJ, Viviani S, Pham HT, Innis BL. Chokephaibulkit K, et al. Among authors: viviani s. Vaccine. 2022 Apr 1;40(15):2352-2361. doi: 10.1016/j.vaccine.2021.10.076. Epub 2021 Nov 14. Vaccine. 2022. PMID: 34789403 Free PMC article. Clinical Trial.
Antibody Persistence 1-5 Years Following Vaccination With MenAfriVac in African Children Vaccinated at 12-23 Months of Age.
Tapia MD, Findlow H, Idoko OT, Preziosi MP, Kulkarni PS, Enwere GC, Elie C, Parulekar V, Sow SO, Haidara FC, Diallo F, Doumbia M, Akinsola AK, Adegbola RA, Kampmann B, Chaumont J, Martellet L, Marchetti E, Viviani S, Tang Y, Plikaytis BD, LaForce FM, Carlone G, Borrow R. Tapia MD, et al. Among authors: viviani s. Clin Infect Dis. 2015 Nov 15;61 Suppl 5(Suppl 5):S514-20. doi: 10.1093/cid/civ672. Clin Infect Dis. 2015. PMID: 26553683 Free PMC article. Clinical Trial.
Safety Monitoring in Group A Meningococcal Conjugate Vaccine Trials: Description, Challenges, and Lessons.
Enwere GC, Paranjape G, Kulkarni PS, Ginde M, Hartmann K, Viviani S, Chaumont J, Martellet L, Makadi MF, Ivinson K, Marchetti E, Herve J, Kertson K, LaForce FM, Preziosi MP. Enwere GC, et al. Among authors: viviani s. Clin Infect Dis. 2015 Nov 15;61 Suppl 5(Suppl 5):S501-6. doi: 10.1093/cid/civ509. Clin Infect Dis. 2015. PMID: 26553681 Free PMC article. Review.
180 results